Antisense protein kinase A RIα acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: Molecular basis for combinatorial therapy

Clinical Cancer Research

Volumn 9, Issue 3, 2003, Pages 1171-1178

  Cho, Yee Sook ^a   Cho Chung, Yoon S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CAMPTOTHECIN DERIVATIVE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DNA TOPOISOMERASE; HYDROXYCAMPTOTHECIN; PROTEIN BAD; PROTEIN BAX; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL STRUCTURE; COLON CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME SUBUNIT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-ASSOCIATED DEATH PROTEIN; BLOTTING, WESTERN; CAMPTOTHECIN; CARRIER PROTEINS; CELL DIVISION; COLONIC NEOPLASMS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DNA TOPOISOMERASES, TYPE I; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; MALE; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; OLIGORIBONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0037341359     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Krebs, E. G., and Beavo, J. A. Phosphorylation-dephosphorylation of enzymes. Rev. Biochem., 48: 923-939, 1979.
2. Beebe, S. J., and Corbin, J. D. Cyclic nucleotide-dependent protein kinases. In: S. J. Beebe and J. D. Corbin (eds.), The Enzymes: Control by Phosphorylation, Vol. 17, part A, pp. 43-111. New York: Academic Press, 1986.
3. Tortora, G., Pepe, S., Bianco, C., Baldassarre, G., Budillon, A., Clair, T., Cho-Chung, Y. S., Bianco, A. R., and Ciardiello, F. The RIα subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells. Oncogene, 9: 3233-3240, 1994.
4. Tortora, G., Pepe, S., Cirafici, A. M., Ciardiello, F., Porcellini, A., Clair, T., Colletta, G., Cho-Chung, Y. S., and Bianco, A. R. Thyroid-stimulating hormone-regulated growth and cell cycle distribution of thyroid cells involve type I isozyme of cyclic AMP-dependent protein kinase. Cell Growth Differ., 4: 359-365, 1993.
5. Miller, W. R., Hulme, M. J., Cho-Chung, Y. S., and Elton, R. A. Types of cyclic AMP binding proteins in human breast cancers. Eur. J. Cancer, 29A: 989-991, 1993.
6. Miller, W. R., Watson, D. M. A., Jack, W., Chetty, U., and Elton, R. A. Tumor cyclic AMP binding proteins: An independent prognostic factor for disease recurrence and survival in breast cancer. Breast Cancer Res Treat., 26: 89-94, 1993.
7. Simpson, B. J. B., Ramage, A. D., Hulme, M. J., Burns, D. J., Katsaros, D., Langdon, S. P., and Miller, W. R. Cyclic adenosine 3′, 5′-monophosphate-binding proteins in human ovarian cancer: correlations with clinicopathological features. Clin. Cancer Res., 2: 201-206, 1996.
8. McDaid, H. M., Cairns, M. T., Atkinson, R. I., McAleer, S., Harkin, D. P., Gilmore, P., and Johnston, P. G. Increased expression of the RIα subunit of the cAMP-dependent protein kinase A is associated with advanced stage of ovarian cancer. Br. J. Cancer, 79: 933-939, 1999.
9. Cho-Chung, Y. S., Pepe, S., Clair, T., Budillon, A., and Nesterova, M. cAMP-dependent protein kinase: role in normal and malignant growth. Crit. Rev. Oncol. Hematol., 21: 33-61, 1995.
10. Cho-Chung, Y. S., Nesterova, M., Pepe, S., Lee, G. R., Noguchi, K., Srivastava, R. K., Srivastava, A. R., Alper, O., Park, Y. G., and Lee, Y. N. Antisense DNA-targeting protein kinase A-RIα subunit: a novel approach to cancer treatment. Front Biosci., 4: D898-907, 1999.
11. Tortora, G., and Ciardiello, F. Targeting of epidermal growth factor receptor and protein kinase A: molecular basis and therapeutic applications. Ann. Oncol., 11: 777-783, 2000.
12. Nesterova, M., and Cho-Chung, Y. S. A single-injection protein kinase A-directed antisense treatment to inhibit humor growth. Nat. Med., 1: 528-633, 1995.
13. Nesterova, M., and Cho-Chung, Y. S. Oligonucleotide sequence-specific inhibition of gene expression, tumor growth inhibition, and modulation of cAMP signaling by an RNA-DNA hybrid antisense targeted to protein kinase A RIα subunit. Antisense Nucleic Acid Drug Dev., 10: 423-433, 2000.
14. Cho, Y. S., Kim, M.-K., Tan, L., Srivastava, R., Agrawal, S., and Cho-Chung, Y. S. Protein kinase A RIα antisense inhibition of PC3M prostate cancer growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylaton. Clin. Cancer Res., 8: 607-614, 2002.
15. Wang, H., Cai, Q., Zeng, X., Yu, D., Agrawal, S., and Zhang, M. Q. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIα subunit of protein kinase A after oral administration. Proc. Natl. Acad. Sci. USA, 96: 13989-13994, 1999.
16. Cho, Y. S., Kim, M.-K., Cheadle, C., Neary, C., Becker, K. G., and Cho-Chung, Y. S. Antisense DNAs as multisite genomic modulators identified by DNA microarray. Proc. Natl. Acad. Sci. USA, 98: 9819-9823, 2001.
17. Zangemeister-Wittke, U., Schenker, T., Luedke, G. H., and Stahel, R. A. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br. J. Cancer., 78: 1035-1042, 1998.
18. Wang, H., Zeng, X., Oliver, P., Le, L. P., Chen, J., Chen, L., Zhou, W., Agrawal, S., and Zhang, R. MDM2 oncogene as a target for cancer therapy: an antisense approach. Int. J. Oncol., 15: 653-660, 1999.
19. Tortora, G., Caputo, R., Damiano, V., Bioance, R., Peppe, S., Bianco, A. R., Jiang, Z., Agrawal, S., and Ciardiello, F. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotides targeting protein kinase A. Proc. Natl. Acad. Sci. USA, 94: 12586-12591, 1997.
20. Tortora, G., Caputo, R., Pomatico, G., Pepe, S., Bianco, A. R., Agrawal, S., Mendelsohn, J., and Ciardiello, F. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. Clin. Cancer Res., 5: 875-881, 1999.
21. Agrawal, S., and Kandimalla, E. R. Antisense therapeutics: is it as simple as complementary base recognition? Mol. Med. Today, 6: 72-81, 2000.
22. Uhlmann, E. Oligonucleotide technologies: synthesis, production, regulations and applications. 29-30th Nov 2000. Hamburg, Germany. Expert Opin. Biol. Ther., 1: 319-328, 2001.
23. Cho-Chung, Y. S. Antisense and therapeutic oligonucleotides: toward a gene-targeting cancer clinic. Expert Opin. Ther. Patents, 10: 1711-1724, 2000.
24. Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., McPhail, A. T., and Sim, G. A. Plant antitumor agents: I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc., 88: 3888-3890, 1966.
25. Wall, M. E., and Wani, M. C. Camptothecin and analogs: from discovery to clinic. In: M. Potmesol and H. Pinedo (eds.), Camptothecins: New Anticancer Agents, pp. 21-41. Boca Raton, FL: CRC Press, 1995.
26. 2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res., 52: 1823-1829, 1992.
27. Tsao, Y. P., Russo, A., Nyamuswa, G., Silber, R., and Liu, L. F. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res., 53: 5908-5914, 1993.
28. Ryan, A. J., Squires, S., Strutt, H. L., Evans, A., and Johnson, R. T. Different fates of camptothecin-induced replication fork-associated double-strand DNA breaks in mammalian cells. Carcinogenesis (Lond.), 15: 823-828, 1994.
29. Binaschi, M., Zunino, F., and Capranico, G. Mechanism of action of DNA topoisomerase inhibitors. Stem Cells, 13: 369-379, 1995.
30. Zhang, R., Cai, Q., Lindsey, J. R., Li, Y., Chambless, B., and Naguib, F. N. M. Antitumor activity and pharmacokinetics following oral administration of natural product DNA topoisomerase inhibitors 10-hydroxycampthothecin and camptothecin in SCID mice bearing human breast cancer xenografts. Int. J. Oncol., 10: 1147-1156, 1997.
31. Potmesil, M., and Glovanella, B. C. Preclinical development of 20(S)-camptothecin, 9-aminocamptothecin, and other analogues. In: M. Potmesol and H. Pinedo (eds.), Camptothecins: New Anticancer Agents, pp. 41-57. Boca Raton, FL: CRC Press, 1995.
32. Cai, Q., Lindsey, J. R., and Zhang, R. Regression of human colon cancer xenografts in SCID mice following oral administration of water-insoluble camptothecins. Int. J. Cancer, 10: 953-960, 1997.
33. Wani, M. C., and Wall, M. E. Plant antitumor agents II. The structure of two new alkaloids from Camptotheca acuminata. J. Org. Chem., 51: 1364-1367, 1969.
34. Ling, Y. H., Perez-Soler, R., and Tseng, M. T. Effect of DNA topoisomerase I inhibitor, 10-hydroxycamptothecin, on the structure and function of nuclei and nuclear matrix in bladder carcinoma MBT-2 cells. Anticancer Res., 13: 1613-1618, 1993.
35. Ling, Y. H., and Xu, B. Inhibition of phosphorylation of histone H1 and H3 induced by 10- hydroxycamptothecin. DNA topoisomerase I inhibitor, in murine ascites hepatoma cells. Acta Pharmacol. Sin., 14: 546-550, 1993.
36. Chen, H. X., Marshall, J. L., Ness, E., Martin, R. R., Dvorchik, B., Rizvi, N., Marquis, I., McKinlay, M., Dahut, W., and Hawkins, M. J. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (Gem231) targeting the type I protein kinase A by 2-hour infusions in patients with refractory solid tumors. Clin. Cancer Res., 6: 1259-1266, 2000.
37. Cho, Y. S., Park, Y. G., Lee, Y. N., Kim, M. K., Bates, S., Tan, L., and Cho-Chung, Y. S. Extracellular protein kinase A as a cancer biomarker: its expression by tumor cells and reversal by a myristate-lacking Cα and RIIβ subunit overexpression. Proc. Natl. Acad. Sci. USA, 97: 835-840, 2000.
38. Srivastava, R. K., Srivastava, A. R., Korsmeyer, S. J., Nesterova, M., Cho-Chung, Y. S., and Longo, D. L. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol. Cell. Biol., 18: 3509-3517, 1998.
39. Harada, H., Becknell, B., Wilm, M., M., M., Huang, L. J., Taylor, S. S., Scott, J. D., and Korsmeyer, S. J. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol. Cell, 3: 413-422, 1999.
40. Roesler, W. J., Vandenbark, G. R., and Hanson, R. W. Cyclic AMP and the induction of eukaryotic gene transcription. J. Biol. Chem., 263: 9063-9066, 1988.
41. Neary, C. L., and Cho-Chung, Y. S. Nuclear translocation of the catalytic subunit of protein kinase A induced by an antisense oligonucleotide directed against the RIα regulatory subunit. Oncogene, 20: 8019-8024, 2001.
42. 1 phase of nontransformed mammalian cells are absent in transformed cells. Proc. Natl. Acad. Sci. USA, 89: 8626-8630, 1992.
43. Nesterova, M., Noguchi, K., Park, Y. G., Lee, Y. N., and Cho-Chung, Y. S. Compensatory stabilization of RIIβ protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense-directed down-regulation of protein kinase A RIα protein. Clin. Cancer Res., 6: 3434-3441, 2000.
44. Cho-Chung, Y. S., Nesterova, M., Kondrashin, A., Noguchi, K., Srivastava, R. K., and Pepe, S. Antisense-protein kinase A: a single-gene-based therapeutic approach. Antisense and Nucleic Acid Drug Dev., 7: 217, 1997.